Home New England Cambridge, MA Vedanta Biosciences, Inc. COMPANY
Clinical Phase 3
Also known as Home - Vedanta Biosciences, Inc · 1 open job · last seen Oct 23, 2026 · 6 sources
Keywords: clostridium difficile infection gastroenterology Clostridium Difficile Infection Recurrence Clostridioides Difficile Infection Clostridioides Difficile Infection Recurrence CDI Ulcerative Colitis C. Diff Infection Recurrent Clostridium Difficile Infection C.Difficile Diarrhea Diarrhea Infectious Melanoma Gastric Cancer Gastroesophageal Junction Adenocarcinoma Colorectal Cancer Clostridioides Difficile VE303 VE202 VE800 Show all 19 keywords
Location: Cambridge, MA · source · Oct 15, 2026
Profile checked Oct 10, 2026
At a glance HQ Cambridge, MA source Region New England Stage Clinical Phase 3 Latest trial Phase 3: VE303 for Prevention of Recurrent Clostridioides Difficile Infection (May 20, 2024) source Raises and deals from press releases Raise Undisclosed round · $60M · announced Aug 6, 2026 Company release ↗ Source quote Aug 6, 2026 · Company release ↗ “– Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced securing $60 million in funding” Raises announced in these releases: $60M disclosed.
From the company’s own releases; this list is partial. All raises and deals
Timeline Aug 6, 2026 Raise Private equity round: $60M (total, as published), announced Aug 6, 2026. Source: company's own press page. source ↗ Aug 6, 2026 Raise Undisclosed round · $60M source ↗ May 20, 2024 Trial start Phase 3: VE303 for Prevention of Recurrent Clostridioides Difficile Infection source ↗ May 8, 2023 Trial start Phase 2: VE202 in Patients With Mild-to-Moderate Ulcerative Colitis source ↗ Jan 23, 2020 Trial start Phase 1/Phase 2: Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer source ↗ Feb 8, 2019 Trial start 2: Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection source ↗ Nov 28, 2017 Trial start Phase 1: First-in-human Study of VE303 in Healthy Adult Volunteers source ↗ Upcoming milestones 2027-06 (ESTIMATED) · Phase 3 · VE303 for Prevention of Recurrent Clostridioides Difficile Infection · NCT06237452 Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding Raised: $60.0M. Last 2 years.
Aug 6, 2026 Private equity round: $60M (total, as published), announced Aug 6, 2026. Source: company's own press page. source ↗ Clinical trials (lead sponsor) 5 Record Title Phase Status Start Primary completion NCT06237452 VE303 for Prevention of Recurrent Clostridioides Difficile Infection Phase 3 Recruiting May 20, 2024 2027-06 (estimated) NCT05370885 VE202 in Patients With Mild-to-Moderate Ulcerative Colitis Phase 2 Terminated May 8, 2023 Aug 29, 2025 (actual) NCT04208958 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer Phase 1/Phase 2 Completed Jan 23, 2020 Aug 26, 2021 (actual) NCT03788434 Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection 2 Completed Feb 8, 2019 Jun 2, 2021 (actual) NCT04236778 First-in-human Study of VE303 in Healthy Adult Volunteers Phase 1 Completed Nov 28, 2017 Mar 11, 2019 (actual)
Open jobs 1 Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
Connect See your connections at Vedanta Biosciences on LinkedIn (search by name, results not checked) LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.
LinkedIn page linked from the company's own site: source · seen 2026-10-18
